Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Prostate Cancer

  Free Subscription


Articles published in J Nucl Med

Retrieve available abstracts of 109 articles:
HTML format
Text format



Single Articles


    May 2019
  1. CARRASQUILLO JA, Fine B, Pandit-Taskar N, Larson SM, et al
    Imaging metastatic castration-resistant prostate cancer patients with (89)Zr-DFO-MSTP2109A anti-STEAP1 antibody.
    J Nucl Med. 2019 May 3. pii: jnumed.118.222844. doi: 10.2967/jnumed.118.222844.
    PubMed     Text format     Abstract available


    April 2019
  2. PIRON S, De Man K, Van Laeken N, D'Asseler Y, et al
    Radiation dosimetry and biodistribution of (18)F-PSMA-11 for PET imaging of prostate cancer.
    J Nucl Med. 2019 Apr 26. pii: jnumed.118.225250. doi: 10.2967/jnumed.118.225250.
    PubMed     Text format     Abstract available


  3. JANSEN BHE, Yaqub M, Voortman J, Cysouw MCF, et al
    Simplified Methods for Quantification of (18)F-DCFPyL Uptake in Patients with Prostate Cancer.
    J Nucl Med. 2019 Apr 18. pii: jnumed.119.227520. doi: 10.2967/jnumed.119.227520.
    PubMed     Text format     Abstract available


  4. ROUSSEAU E, Wilson D, Lacroix-Poisson F, Krauze A, et al
    A Prospective Study on (18)F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer.
    J Nucl Med. 2019 Apr 12. pii: jnumed.119.226381. doi: 10.2967/jnumed.119.226381.
    PubMed     Text format     Abstract available


  5. ABIODUN-OJO OA, Akintayo AA, Akin-Akintayo OO, Tade FI, et al
    (18)F-Fluciclovine parameters on targeted prostate biopsy associated with true positivity in recurrent prostate cancer.
    J Nucl Med. 2019 Apr 6. pii: jnumed.119.227033. doi: 10.2967/jnumed.119.227033.
    PubMed     Text format     Abstract available


    March 2019
  6. JADVAR H, Velez E, Desai B, Ji L, et al
    Prediction of time to hormonal treatment failure in metastatic castrate-sensitive prostate cancer with (18)F-FDG PET/CT.
    J Nucl Med. 2019 Mar 29. pii: jnumed.118.223263. doi: 10.2967/jnumed.118.223263.
    PubMed     Text format     Abstract available


  7. RAHBAR K, Hofman MS, Schrader AJ, Boegemann M, et al
    A Self-Fulfilling Prophecy: Comparing (177)Lu-PSMA Radioligand therapy in Taxane Naive vs Post-Taxane metastasized Prostate Cancer Patients?
    J Nucl Med. 2019 Mar 29. pii: jnumed.119.228742. doi: 10.2967/jnumed.119.228742.
    PubMed     Text format    


  8. SOEDA F, Watabe T, Naka S, Liu Y, et al
    Impact of (18)F-PSMA-1007 uptake in prostate cancer using different peptide concentrations: preclinical PET/CT study in mice.
    J Nucl Med. 2019 Mar 22. pii: jnumed.118.223479. doi: 10.2967/jnumed.118.223479.
    PubMed     Text format     Abstract available


  9. EKMEKCIOGLU O, Busstra M, Klass ND, Verzijlbergen F, et al
    Bridging the imaging gap: PSMA PET/CT has a high impact on treatment planning in prostate cancer patients with biochemical recurrence - a narrative review of literature.
    J Nucl Med. 2019 Mar 8. pii: jnumed.118.222885. doi: 10.2967/jnumed.118.222885.
    PubMed     Text format     Abstract available


  10. ZHANG J, Kulkarni HR, Singh A, Schuchardt C, et al
    (177)Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney.
    J Nucl Med. 2019 Mar 8. pii: jnumed.118.223149. doi: 10.2967/jnumed.118.223149.
    PubMed     Text format     Abstract available


  11. SCHWENCK J, Olthof SC, Pfannenberg C, Reischl G, et al
    Intention to treat analysis of (68)Ga-PSMA and (11)C-choline PET/CT versus CT for prostate cancer recurrences after surgery.
    J Nucl Med. 2019 Mar 8. pii: jnumed.118.224543. doi: 10.2967/jnumed.118.224543.
    PubMed     Text format     Abstract available


  12. KRAMER GM, Yaqub M, Vargas HA, Schuit R, et al
    Assessment of simplified methods for quantification of (18)F-FDHT uptake in patients with metastatic castration-resistant prostate cancer.
    J Nucl Med. 2019 Mar 8. pii: jnumed.118.220111. doi: 10.2967/jnumed.118.220111.
    PubMed     Text format     Abstract available


  13. GAFITA A, Bieth M, Kroenke M, Tetteh G, et al
    qPSMA: a semi-automatic software for whole-body tumor burden assessment in prostate cancer using (68)Ga-PSMA11 PET/CT.
    J Nucl Med. 2019 Mar 8. pii: jnumed.118.224055. doi: 10.2967/jnumed.118.224055.
    PubMed     Text format     Abstract available


    February 2019
  14. LIU T, Liu C, Xu X, Liu F, et al
    Preclinical evaluation and pilot clinical study of Al(18)F-PSMA-BCH for prostate cancer imaging.
    J Nucl Med. 2019 Feb 22. pii: jnumed.118.221671. doi: 10.2967/jnumed.118.221671.
    PubMed     Text format     Abstract available


    January 2019
  15. BARBER TW, Singh A, Kulkarni HR, Niepsch K, et al
    Clinical outcomes of (177)Lu-PSMA radioligand therapy in taxane chemotherapy pretreated and taxane chemotherapy naive patients with metastatic castration resistant prostate cancer.
    J Nucl Med. 2019 Jan 25. pii: jnumed.118.216820. doi: 10.2967/jnumed.118.216820.
    PubMed     Text format     Abstract available


  16. JILG CA, Drendel V, Rischke HC, Beck TIR, et al
    Detection Rate of (18)F-choline-PET/CT and (68)Ga-PSMA-HBED-CC-PET/CT for Prostate Cancer Lymph Node Metastases with Direct Link from PET to Histopathology: Dependence on the Size of Tumor Deposits in Lymph Nodes.
    J Nucl Med. 2019 Jan 25. pii: jnumed.118.220541. doi: 10.2967/jnumed.118.220541.
    PubMed     Text format     Abstract available


  17. BURGER IA, Muller J, Donati OF, Ferraro DA, et al
    (68)Ga-PSMA-11 PET/MR detects local recurrence occult on mpMRI in prostate cancer patients after HIFU.
    J Nucl Med. 2019 Jan 25. pii: jnumed.118.221564. doi: 10.2967/jnumed.118.221564.
    PubMed     Text format     Abstract available


  18. JOCHUMSEN MR, Tolbod LP, Pedersen BG, Nielsen MM, et al
    Quantitative tumor perfusion imaging with (82)Rubidium-PET/CT in prostate cancer - analytical and clinical validation.
    J Nucl Med. 2019 Jan 25. pii: jnumed.118.219188. doi: 10.2967/jnumed.118.219188.
    PubMed     Text format     Abstract available


    December 2018
  19. MAURER T, van Leeuwen FWB, Schottelius M, Wester HJ, et al
    Entering the era of molecular-targeted precision surgery in recurrent prostate cancer.
    J Nucl Med. 2018 Dec 20. pii: jnumed.118.221861. doi: 10.2967/jnumed.118.221861.
    PubMed     Text format    


  20. SCHMIDT-HEGEMANN NS, Chukwuka E, Minglun L, Rogowski P, et al
    Impact of (68)Ga-PSMA-PET/CT on the radiotherapeutic approach for prostate cancer in comparison to CT - a retrospective analysis.
    J Nucl Med. 2018 Dec 14. pii: jnumed.118.220855. doi: 10.2967/jnumed.118.220855.
    PubMed     Text format     Abstract available


  21. CHEN M, Zhang Q, Zhang C, Zhao X, et al
    Combination of (68)Ga-PSMA PET/CT and multiparameter MRI improves the detection of clinically significant prostate cancer: a lesion by lesion analysis.
    J Nucl Med. 2018 Dec 14. pii: jnumed.118.221010. doi: 10.2967/jnumed.118.221010.
    PubMed     Text format     Abstract available


  22. EMMETT LM, Yin C, Crumbaker M, Hruby G, et al
    Rapid modulation of PSMA expression by Androgen deprivation: Serial (68)Ga PSMA-11 PET in men with hormone sensitive and castrate resistant prostate cancer commencing androgen blockade.
    J Nucl Med. 2018 Dec 14. pii: jnumed.118.223099. doi: 10.2967/jnumed.118.223099.
    PubMed     Text format     Abstract available


  23. HOPE TA, Goodman JZ, Allen IE, Calais J, et al
    Meta-analysis of (68)Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology.
    J Nucl Med. 2018 Dec 7. pii: jnumed.118.219501. doi: 10.2967/jnumed.118.219501.
    PubMed     Text format     Abstract available


    November 2018
  24. BEHR SC, Aggarwal R, Van Brocklin HF, Flavell RR, et al
    First-in-Human Phase I study of CTT1057, a Novel (18)F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer.
    J Nucl Med. 2018 Nov 21. pii: jnumed.118.220715. doi: 10.2967/jnumed.118.220715.
    PubMed     Text format     Abstract available


    October 2018
  25. VIOLET JA, Jackson P, Ferdinandus J, Sandhu S, et al
    Dosimetry of Lu-177 PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pre-therapeutic imaging and "whole body" tumor dosimetry with treatment outcomes.
    J Nucl Med. 2018 Oct 5. pii: jnumed.118.219352. doi: 10.2967/jnumed.118.219352.
    PubMed     Text format     Abstract available


    September 2018
  26. SCHOTTELIUS M, Wurzer A, Wissmiller K, Beck R, et al
    Synthesis and preclinical characterization of the PSMA-targeted hybrid tracer PSMA-I&F for nuclear and fluorescence imaging of prostate cancer.
    J Nucl Med. 2018 Sep 20. pii: jnumed.118.212720. doi: 10.2967/jnumed.118.212720.
    PubMed     Text format     Abstract available


  27. YIN Y, Werner RA, Higuchi T, Lapa C, et al
    Follow-Up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.
    J Nucl Med. 2018 Sep 6. pii: jnumed.118.217653. doi: 10.2967/jnumed.118.217653.
    PubMed     Text format     Abstract available


    August 2018
  28. ROUSSEAU E, Lau J, Kuo HT, Zhang Z, et al
    Monosodium glutamate reduces (68)Ga-PSMA-11 uptake in salivary glands and kidneys in preclinical prostate cancer model.
    J Nucl Med. 2018 Aug 10. pii: jnumed.118.215350. doi: 10.2967/jnumed.118.215350.
    PubMed     Text format     Abstract available


    July 2018
  29. JADVAR H
    Oligometastatic prostate cancer: molecular imaging and clinical management implications in the era of precision oncology.
    J Nucl Med. 2018 Jul 20. pii: jnumed.118.213470. doi: 10.2967/jnumed.118.213470.
    PubMed     Text format    


  30. KOERBER SA, Will L, Kratochwil C, Haefner MF, et al
    (68)Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients.
    J Nucl Med. 2018 Jul 5. pii: jnumed.118.211086. doi: 10.2967/jnumed.118.211086.
    PubMed     Text format     Abstract available


    May 2018
  31. LARIMER BM, Dubois F, Bloch E, Nesti S, et al
    Specific (18)F-FDHT Accumulation in Human Prostate Cancer Xenograft Murine Models is Facilitated by Pre-Binding to Sex Hormone Binding Globulin.
    J Nucl Med. 2018 May 31. pii: jnumed.118.208785. doi: 10.2967/jnumed.118.208785.
    PubMed     Text format     Abstract available


  32. THALGOTT M, Duwel C, Rauscher I, Heck MM, et al
    One-stop shop whole-body (68)Ga-PSMA-11 PET/MRI compared to clinical Nomograms for preoperative T- and N-Staging of High-Risk Prostate Cancer.
    J Nucl Med. 2018 May 24. pii: jnumed.117.207696. doi: 10.2967/jnumed.117.207696.
    PubMed     Text format     Abstract available


  33. DOUGHTON JA, Hofman MS, Eu P, Hicks RJ, et al
    A first-in-man study of (68)Ga-nanocolloid PET-CT sentinel lymph node imaging in prostate cancer demonstrates aberrant lymphatic drainage pathways.
    J Nucl Med. 2018 May 4. pii: jnumed.118.209171. doi: 10.2967/jnumed.118.209171.
    PubMed     Text format     Abstract available


  34. ELSCHOT M, Selnaes KM, Johansen H, Kruger-Stokke B, et al
    The Effect of Including Bone in DIXON-based Attenuation Correction for (18)F-fluciclovine PET/MRI of Prostate Cancer.
    J Nucl Med. 2018 May 4. pii: jnumed.118.208868. doi: 10.2967/jnumed.118.208868.
    PubMed     Text format     Abstract available


    April 2018
  35. CALAIS J, Kishan AU, Cao M, Fendler WP, et al
    Potential impact of (68)Ga-PSMA-11 PET/CT on prostate cancer definitive radiation therapy planning.
    J Nucl Med. 2018 Apr 13. pii: jnumed.118.209387. doi: 10.2967/jnumed.118.209387.
    PubMed     Text format     Abstract available


  36. AHMADZADEHFAR H, Essler M
    Predictive factors of response and overall survival in patients with castration-resistant metastatic prostate cancer undergoing (177)Lu-PSMA therapy.
    J Nucl Med. 2018 Apr 13. pii: jnumed.118.209270. doi: 10.2967/jnumed.118.209270.
    PubMed     Text format    


  37. GRKOVSKI M, Gharzeddine K, Sawan P, Schoder H, et al
    (11)C-choline pharmacokinetics in recurrent prostate cancer.
    J Nucl Med. 2018 Apr 6. pii: jnumed.118.210088. doi: 10.2967/jnumed.118.210088.
    PubMed     Text format     Abstract available


  38. VARGAS HA, Kramer GM, Scott AM, Weickhardt A, et al
    Reproducibility and repeatability of semi-quantitative (18)F-fluorodihydrotestosterone (FDHT) uptake metrics in castration-resistant prostate cancer metastases: a prospective multi-center study.
    J Nucl Med. 2018 Apr 6. pii: jnumed.117.206490. doi: 10.2967/jnumed.117.206490.
    PubMed     Text format     Abstract available


    March 2018
  39. HARMON SA STEPHANIE., Bergvall E, Mena E, Shih JH, et al
    A Prospective Comparison of (18)F-Sodium Fluoride PET/CT and PSMA-targeted (18)F-DCFBC PET/CT in Metastatic Prostate Cancer.
    J Nucl Med. 2018 Mar 30. pii: jnumed.117.207373. doi: 10.2967/jnumed.117.207373.
    PubMed     Text format     Abstract available


  40. ZETTLITZ KA, Tsai WK, Knowles SM, Kobayashi N, et al
    Dual-modality immunoPET and near-infrared fluorescence (NIRF) imaging of pancreatic cancer using an anti-prostate cancer stem cell antigen (PSCA) cys-diabody.
    J Nucl Med. 2018 Mar 30. pii: jnumed.117.207332. doi: 10.2967/jnumed.117.207332.
    PubMed     Text format     Abstract available


  41. LUCKERATH K, Stuparu AD, Wei L, Kim W, et al
    Detection threshold and reproducibility of (68)Ga-PSMA11 PET/CT in a mouse model of prostate cancer.
    J Nucl Med. 2018 Mar 30. pii: jnumed.118.207704. doi: 10.2967/jnumed.118.207704.
    PubMed     Text format     Abstract available


  42. PARENT EE, Schuster DM
    Update on (18)F-fluciclovine PET for prostate cancer imaging.
    J Nucl Med. 2018 Mar 9. pii: jnumed.117.204032. doi: 10.2967/jnumed.117.204032.
    PubMed     Text format     Abstract available


  43. CALAIS J, Fendler WP, Herrmann K, Eiber M, et al
    Reply: Comparison of (68)Ga-PSMA-11 and (18)F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective trial is on its way.
    J Nucl Med. 2018 Mar 1. pii: jnumed.118.209965. doi: 10.2967/jnumed.118.209965.
    PubMed     Text format    


  44. WONDERGEM M, van der Zant F, Vlottes P, Knol R, et al
    Effects of fasting on (18)F-DCFPyL uptake in prostate cancer lesions and tissues with known high physiologic uptake.
    J Nucl Med. 2018 Mar 1. pii: jnumed.117.207316. doi: 10.2967/jnumed.117.207316.
    PubMed     Text format     Abstract available


  45. HICKS RJ
    The Injustice of Being Judged by the Errors of Others: The Tragic Tale of the Battle for PET Reimbursement.
    J Nucl Med. 2018;59:418-420.
    PubMed     Text format    


  46. LUTJE S, Gerrits D, Molkenboer-Kuenen JD, Herrmann K, et al
    Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
    J Nucl Med. 2018;59:494-501.
    PubMed     Text format     Abstract available


    February 2018
  47. DENES B, Gardiner P
    Comparison of (68)Ga-PSMA-11 PET/CT and (18)F-Fluciclovone PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Interesting, but Far from Definitive.
    J Nucl Med. 2018 Feb 23. pii: jnumed.118.209817. doi: 10.2967/jnumed.118.209817.
    PubMed     Text format    


  48. GIESEL F, Will L, Kesch C, Freitag M, et al
    Biochemical recurrence of prostate cancer: initial results with (18)F-PSMA-1007 PET/CT.
    J Nucl Med. 2018 Feb 1. pii: jnumed.117.196329. doi: 10.2967/jnumed.117.196329.
    PubMed     Text format     Abstract available


  49. WEBER W
    2017 SNMMI Highlights Lecture: Oncology, Part 2.
    J Nucl Med. 2018;59:9N-15N.
    PubMed     Text format    


    January 2018
  50. RATHKE H, Afshar-Oromieh A, Giesel FL, Kremer C, et al
    Intra-individual comparison of Tc-99m-MDP bone scan and the PSMA-ligand Tc-99m-MIP-1427 in patients with osseous metastasized prostate cancer.
    J Nucl Med. 2018 Jan 25. pii: jnumed.117.200220. doi: 10.2967/jnumed.117.200220.
    PubMed     Text format     Abstract available


  51. RISCHPLER C, Beck TI, Okamoto S, Schlitter AM, et al
    (68)Ga-PSMA-HBED-CC uptake in cervical, coeliac and sacral ganglia as an important pitfall in prostate cancer PET imaging.
    J Nucl Med. 2018 Jan 25. pii: jnumed.117.204677. doi: 10.2967/jnumed.117.204677.
    PubMed     Text format     Abstract available


  52. ROWE SP, Pomper MG, Gorin MA
    Molecular Imaging of Prostate Cancer: Choosing the Right Agent.
    J Nucl Med. 2018 Jan 25. pii: jnumed.117.206318. doi: 10.2967/jnumed.117.206318.
    PubMed     Text format    


  53. CALAIS J, Cao M, Nickols NG
    The Utility of PET/CT in External Radiation Therapy Planning of Prostate Cancer.
    J Nucl Med. 2018 Jan 4. pii: jnumed.117.196444. doi: 10.2967/jnumed.117.196444.
    PubMed     Text format     Abstract available


  54. WEBER W
    2017 SNMMI Highlights Lecture: Oncology.
    J Nucl Med. 2018;59:7N-13N.
    PubMed     Text format    


    December 2017
  55. GIESEL F, Will L, Lawal I, Lengana T, et al
    Intra-individual comparison of (18)F-PSMA-1007 and (18)F-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: A pilot study.
    J Nucl Med. 2017 Dec 21. pii: jnumed.117.204669. doi: 10.2967/jnumed.117.204669.
    PubMed     Text format     Abstract available


  56. CALAIS J, Fendler WP, Herrmann K, Eiber M, et al
    Head-to-head comparison of (68)Ga-PSMA-11 PET/CT and (18)F-Fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence.
    J Nucl Med. 2017 Dec 14. pii: jnumed.117.203257. doi: 10.2967/jnumed.117.203257.
    PubMed     Text format     Abstract available


  57. CECI F, Fendler W, Eiber M
    A new type of prostate cancer imaging. Will (64)CuCl2 PET/CT flourish or vanish?
    J Nucl Med. 2017 Dec 14. pii: jnumed.117.199885. doi: 10.2967/jnumed.117.199885.
    PubMed     Text format    


  58. JADVAR H, Ballas LK
    PSMA PET: Transformational Change in Prostate Cancer Management?
    J Nucl Med. 2017 Dec 14. pii: jnumed.117.203604. doi: 10.2967/jnumed.117.203604.
    PubMed     Text format    


  59. CALAIS J, Fendler WP, Eiber M, Gartmann J, et al
    Actual impact of (68)Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence.
    J Nucl Med. 2017 Dec 14. pii: jnumed.117.202945. doi: 10.2967/jnumed.117.202945.
    PubMed     Text format     Abstract available


  60. HAMMES J, Tager P, Drzezga A
    EBONI: A tool for automated quantification of bone metastasis load in PSMA PET/CT.
    J Nucl Med. 2017 Dec 14. pii: jnumed.117.203265. doi: 10.2967/jnumed.117.203265.
    PubMed     Text format     Abstract available


    November 2017
  61. BARANSKI AC, Schafer M, Bauder-Wust U, Roscher M, et al
    PSMA-11 Derived Dual-labeled PSMA-Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer.
    J Nucl Med. 2017 Nov 30. pii: jnumed.117.201293. doi: 10.2967/jnumed.117.201293.
    PubMed     Text format     Abstract available


  62. ZHANG J, Niu G, Fan X, Lang L, et al
    Positron Emission Tomography Using a GRPR Antagonist 68Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients.
    J Nucl Med. 2017 Nov 9. pii: jnumed.117.198929. doi: 10.2967/jnumed.117.198929.
    PubMed     Text format     Abstract available


  63. CALAIS J, Czernin J, Cao M, Kishan AU, et al
    68Ga-PSMA PET/CT mapping of prostate cancer biochemical recurrence following radical prostatectomy in 270 patients with PSA<1.0ng/ml: Impact on Salvage Radiotherapy Planning.
    J Nucl Med. 2017 Nov 9. pii: jnumed.117.201749. doi: 10.2967/jnumed.117.201749.
    PubMed     Text format     Abstract available


  64. EIBER M, Herrmann K, Calais J, Hadaschihk B, et al
    PROstate cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT.
    J Nucl Med. 2017 Nov 9. pii: jnumed.117.198119. doi: 10.2967/jnumed.117.198119.
    PubMed     Text format     Abstract available


  65. GIESEL FL, Kopka K
    Reply: PSMA ligands for imaging prostate cancer - alternative labeling by complex formation with Al18F.
    J Nucl Med. 2017 Nov 9. pii: jnumed.117.198176. doi: 10.2967/jnumed.117.198176.
    PubMed     Text format    


    October 2017
  66. MINAMIMOTO R, Sonni I, Hancock S, Vasanawala S, et al
    Prospective Evaluation of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Conventional Imaging.
    J Nucl Med. 2017 Oct 30. pii: jnumed.117.197624. doi: 10.2967/jnumed.117.197624.
    PubMed     Text format     Abstract available


  67. HOFMAN MS, Eu P, Jackson P, Hong E, et al
    Cold Kit PSMA PET Imaging: Phase I study of 68Ga-THP-PSMA PET/CT in patients with prostate cancer.
    J Nucl Med. 2017 Oct 6. pii: jnumed.117.199554. doi: 10.2967/jnumed.117.199554.
    PubMed     Text format     Abstract available


  68. ELSCHOT M, Selnaes KM, Sandsmark E, Kruger-Stokke B, et al
    Combined 18F-Fluciclovine PET/MRI shows potential for detection and characterization of high-risk prostate cancer.
    J Nucl Med. 2017 Oct 6. pii: jnumed.117.198598. doi: 10.2967/jnumed.117.198598.
    PubMed     Text format     Abstract available


  69. DONIN NM, Reiter R
    Why targeting PSMA is a game changer in the management of prostate cancer - a Urologist's point of view.
    J Nucl Med. 2017 Oct 6. pii: jnumed.117.191874. doi: 10.2967/jnumed.117.191874.
    PubMed     Text format     Abstract available


  70. KRATOCHWIL C, Bruchertseifer F, Rathke H, Bronzel M, et al
    Targeted alpha-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding.
    J Nucl Med. 2017;58:1624-1631.
    PubMed     Text format     Abstract available


    September 2017
  71. IAGARU A
    Will GRPR Compete with PSMA as a Target in Prostate Cancer?
    J Nucl Med. 2017 Sep 28. pii: jnumed.117.198192. doi: 10.2967/jnumed.117.198192.
    PubMed     Text format    


  72. FENDLER WP, Cutler C
    More alpha than beta for prostate cancer?
    J Nucl Med. 2017 Sep 21. pii: jnumed.117.198333. doi: 10.2967/jnumed.117.198333.
    PubMed     Text format    


  73. PICCARDO A, Paparo F, Puntoni M, Righi S, et al
    64CuCl2 PET/CT in prostate cancer relapse.
    J Nucl Med. 2017 Sep 8. pii: jnumed.117.195628. doi: 10.2967/jnumed.117.195628.
    PubMed     Text format     Abstract available


  74. FOSBOL MO, Petersen PM, Kjaer A, Mortensen J, et al
    Radium-223 therapy of advanced metastatic castration-resistant prostate cancer: quantitative assessment of skeletal tumor burden for prognostication of clinical outcome and hematological toxicity.
    J Nucl Med. 2017 Sep 1. pii: jnumed.117.195677. doi: 10.2967/jnumed.117.195677.
    PubMed     Text format     Abstract available


  75. SANO K, Kanada Y, Kanazaki K, Ding N, et al
    Brachytherapy with Intratumoral Injections of Radiometal-Labeled Polymers That Thermoresponsively Self-Aggregate in Tumor Tissues.
    J Nucl Med. 2017;58:1380-1385.
    PubMed     Text format     Abstract available


    August 2017
  76. WOYTHAL N, Arsenic R, Kempkensteffen C, Miller K, et al
    Immunohistochemical validation of PSMA-expression measured by 68Ga-PSMA PET/CT in primary prostate cancer.
    J Nucl Med. 2017 Aug 3. pii: jnumed.117.195172. doi: 10.2967/jnumed.117.195172.
    PubMed     Text format     Abstract available


    July 2017
  77. AFAQ A, Alahmed S, Chen SH, Lengana T, et al
    68Ga-PSMA PET/CT impact on prostate cancer management.
    J Nucl Med. 2017 Jul 26. pii: jnumed.117.192625. doi: 10.2967/jnumed.117.192625.
    PubMed     Text format     Abstract available


  78. GRIVAS N, Wit E, Kuusk T, KleinJan G, et al
    The impact of adding sentinel node biopsy to extended pelvic lymph node dissection on the biochemical recurrence of prostate cancer patients treated with robot-assisted radical prostatectomy.
    J Nucl Med. 2017 Jul 26. pii: jnumed.117.195644. doi: 10.2967/jnumed.117.195644.
    PubMed     Text format     Abstract available


  79. EMMETT L EMMETTHRUB, Van Leeuwen P, Nandurkar R, Scheltema MJ, et al
    Treatment outcomes from 68GaPSMA PET CT informed salvage radiation treatment in men with rising PSA following radical prostatectomy: Prognostic value of a negative PSMA PET.
    J Nucl Med. 2017 Jul 26. pii: jnumed.117.196683. doi: 10.2967/jnumed.117.196683.
    PubMed     Text format     Abstract available


  80. SCHWARZENBOCK SM, Rauscher I, Bluemel C, Fendler WP, et al
    PSMA Ligands for PET-Imaging of Prostate Cancer.
    J Nucl Med. 2017 Jul 7. pii: jnumed.117.191031. doi: 10.2967/jnumed.117.191031.
    PubMed     Text format     Abstract available


    June 2017
  81. FENDLER WP, Rahbar K, Herrmann K, Kratochwil C, et al
    177Lu-PSMA radioligand therapy for prostate cancer.
    J Nucl Med. 2017 Jun 29. pii: jnumed.117.191023. doi: 10.2967/jnumed.117.191023.
    PubMed     Text format     Abstract available


  82. AL-MOMANI E, Machulla HJ
    PSMA ligands for imaging prostate cancer - alternative labeling by complex formation with Al18F.
    J Nucl Med. 2017 Jun 29. pii: jnumed.117.197996. doi: 10.2967/jnumed.117.197996.
    PubMed     Text format    


  83. ROACH PJ, Francis R, Emmett L, Hsiao E, et al
    The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study.
    J Nucl Med. 2017 Jun 23. pii: jnumed.117.197160. doi: 10.2967/jnumed.117.197160.
    PubMed     Text format     Abstract available


  84. HOFMAN MS
    Accuracy in the eye of the beholder: can we improve agreement in prostate cancer diagnostics with PSMA PET/CT?
    J Nucl Med. 2017 Jun 21. pii: jnumed.117.192542. doi: 10.2967/jnumed.117.192542.
    PubMed     Text format    


  85. VINSENSIA M, Choyke PL, Hadaschik B, Holland-Letz T, et al
    68Ga-PSMA PET/CT and volumetric morphology of PET-positive lymph nodes stratified by tumor differentiation of prostate cancer.
    J Nucl Med. 2017 Jun 21. pii: jnumed.116.185033. doi: 10.2967/jnumed.116.185033.
    PubMed     Text format     Abstract available


  86. KOERBER SA, Utzinger MT, Kratochwil C, Kesch C, et al
    68Ga-PSMA11-PET/CT in newly diagnosed carcinoma of the prostate: correlation of intraprostatic PSMA uptake with several clinical parameters.
    J Nucl Med. 2017 Jun 15. pii: jnumed.117.190314. doi: 10.2967/jnumed.117.190314.
    PubMed     Text format     Abstract available


  87. OSMAN MM, Iravani A, Hofman MS, Hicks RJ, et al
    Detection of Synchronous Primary Malignancies with 68Ga-PSMA PET/CT in Patients with Prostate Cancer: Frequency in 764 Patients.
    J Nucl Med. 2017 Jun 1. pii: jnumed.117.190215. doi: 10.2967/jnumed.117.190215.
    PubMed     Text format     Abstract available


    May 2017
  88. FENDLER WP, Stuparu AD, Evans-Axelsson S, Luckerath K, et al
    Establishing 177Lu-PSMA-617 radioligand therapy in a syngeneic model of murine prostate cancer.
    J Nucl Med. 2017 May 25. pii: jnumed.117.193359. doi: 10.2967/jnumed.117.193359.
    PubMed     Text format     Abstract available


  89. BIETH M, Kronke M, Tauber R, Dahlbender M, et al
    Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumour Burden in Prostate Cancer using 68Ga-PSMA-PET/CT.
    J Nucl Med. 2017 May 25. pii: jnumed.116.189050. doi: 10.2967/jnumed.116.189050.
    PubMed     Text format     Abstract available


  90. JACOBSON O, Chen H, Niu G, Kiesewetter DO, et al
    PET-guided evaluation and optimization of internalized antibody-drug conjugates targeting erythropoietin producing hepatoma A2 receptor.
    J Nucl Med. 2017 May 25. pii: jnumed.117.192245. doi: 10.2967/jnumed.117.192245.
    PubMed     Text format     Abstract available


  91. HOPE TA, Aggarwal R, Chee B, Tao D, et al
    Impact of Ga-68 PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.
    J Nucl Med. 2017 May 18. pii: jnumed.117.192476. doi: 10.2967/jnumed.117.192476.
    PubMed     Text format     Abstract available


  92. SCHMUCK S, von Klot CA, Henkenberens C, Sohns JM, et al
    Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer.
    J Nucl Med. 2017 May 18. pii: jnumed.117.193581. doi: 10.2967/jnumed.117.193581.
    PubMed     Text format     Abstract available


  93. HADASCHIK B, Boegemann M
    Why Targeting PSMA is a valuable addition in the management of castration-resistant prostate cancer: The Urologists' point of view.
    J Nucl Med. 2017 May 18. pii: jnumed.117.194753. doi: 10.2967/jnumed.117.194753.
    PubMed     Text format    


  94. KESCH C, Vinsensia M, Radtke JP, Schlemmer HP, et al
    Intra-individual comparison of 18F-PSMA-1007-PET/CT, multi-parametric MRI and radical prostatectomy specimen in patients with primary prostate cancer - a retrospective, proof of concept study.
    J Nucl Med. 2017 May 4. pii: jnumed.116.189233. doi: 10.2967/jnumed.116.189233.
    PubMed     Text format     Abstract available


    April 2017
  95. WONDERGEM M, van der Zant F, Knol R, Lazarenko S, et al
    18F-DCFPyL PET/CT in the detection of prostate cancer at 60 and 120 minutes ; detection rate, image quality, activity kinetics and biodistribution.
    J Nucl Med. 2017 Apr 27. pii: jnumed.117.192658. doi: 10.2967/jnumed.117.192658.
    PubMed     Text format     Abstract available


  96. KELLY JM, Amor-Coarasa A, Nikolopoulou A, Wustemann T, et al
    Double Targeting Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer.
    J Nucl Med. 2017 Apr 27. pii: jnumed.116.188722. doi: 10.2967/jnumed.116.188722.
    PubMed     Text format     Abstract available


  97. YOUNG JD, Abbate V, Imberti C, Meszaros LK, et al
    68Ga-THP-PSMA: a PET imaging agent for prostate cancer offering rapid, room temperature, one-step kit-based radiolabeling.
    J Nucl Med. 2017 Apr 13. pii: jnumed.117.191882. doi: 10.2967/jnumed.117.191882.
    PubMed     Text format     Abstract available


  98. FENDLER WP, Calais J, Allen-Auerbach M, Bluemel C, et al
    68Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study.
    J Nucl Med. 2017 Apr 13. pii: jnumed.117.190827. doi: 10.2967/jnumed.117.190827.
    PubMed     Text format     Abstract available


  99. KESCH C, Kratochwil C, Mier W, Kopka K, et al
    Gallium-68 or Fluorine-18 for prostate cancer imaging?
    J Nucl Med. 2017 Apr 13. pii: jnumed.117.190157. doi: 10.2967/jnumed.117.190157.
    PubMed     Text format     Abstract available


  100. MILLER MP, Kostakoglu L, Pryma D, Yu JQ, et al
    Reader training for the re-staging of biochemically recurrent prostate cancer using fluciclovine (18F) PET/CT.
    J Nucl Med. 2017 Apr 6. pii: jnumed.116.188375. doi: 10.2967/jnumed.116.188375.
    PubMed     Text format     Abstract available


    December 2016
  101. LI X, Rowe SP, Leal JP, Gorin MA, et al
    Quantitative Parameters in PSMA-targeted PET Imaging with 18F-DCFPyL: Variability in Normal Organ Uptake.
    J Nucl Med. 2016 Dec 8. pii: jnumed.116.179739.
    PubMed     Text format     Abstract available


    October 2016
  102. JADVAR H
    Radiotheranostics in Prostate Cancer: Introduction and Overview.
    J Nucl Med. 2016;57.
    PubMed     Text format    


    September 2016
  103. HOPE TA, Truillet CC, Ehman EC, Afshar-Oromieh A, et al
    Imaging Response to Androgen Receptor Inhibition Using 68Ga-PSMA-11 PET: First Human Experience.
    J Nucl Med. 2016 Sep 22. pii: jnumed.116.181800.
    PubMed     Text format     Abstract available


  104. JANI A, Schreibmann E, Rossi PJ, Shelton JW, et al
    Impact of Fluciclovine (18F) Positron Emission Tomography on Target Volume Definition for Post-Prostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial.
    J Nucl Med. 2016 Sep 8. pii: jnumed.116.176057.
    PubMed     Text format     Abstract available


    August 2016
  105. D'SOUZA JW, Hensley H, Doss M, Beigarten C, et al
    Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-based Positron Emission Tomography Radiotracers.
    J Nucl Med. 2016 Aug 18. pii: jnumed.116.178780.
    PubMed     Text format     Abstract available


  106. ZHANG J, Niu G, Lang L, Li F, et al
    Clinical translation of a dual integrin alphavbeta3 and GRPR targeting PET radiotracer 68Ga-NOTA-BBN-RGD.
    J Nucl Med. 2016 Aug 4. pii: jnumed.116.177048.
    PubMed     Text format     Abstract available


    July 2016
  107. LIN C, Bradshaw TJ, Perk TG, Harmon S, et al
    Repeatability of Quantitative 18F-NaF PET: A Multicenter Study.
    J Nucl Med. 2016 Jul 21. pii: jnumed.116.177295.
    PubMed     Text format     Abstract available


    May 2016
  108. CYSOUW MC, Kramer GM, Hoekstra OS, Frings V, et al
    Accuracy and precision of partial volume correction in oncological PET/CT studies.
    J Nucl Med. 2016 May 26. pii: jnumed.116.173831.
    PubMed     Text format     Abstract available


    March 2016
  109. PIERT M, Montgomery J, Kunju LP, Siddiqui J, et al
    18F-choline PET/MRI: the Additional Value of PET for MRI-guided Transrectal Prostate Biopsies.
    J Nucl Med. 2016 Mar 16. pii: jnumed.115.170878.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: